Related references
Note: Only part of the references are listed.A liquid chromatographic method for separation of sacubitril-valsartan and their stereoisomeric impurities
Lu Zhou et al.
ANALYTICAL METHODS (2018)
Diode array detection for stability assessment and evaluation of degradation kinetics of newly introduced sacubitril in its supramolecular complex (LCZ696) with valsartan
Marwa A. A. Ragab et al.
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES (2018)
Innovative spectrophotometric methods for simultaneous estimation of the novel two-drug combination: Sacubitril/Valsartan through two manipulation approaches and a comparative statistical study
Maya S. Eissa et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2018)
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects
Yi Han et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
First derivative emission spectrofluorimetric method for the determination of LCZ696, a newly approved FDA supramolecular complex of valsartan and sacubitril in tablets
Marwa A. A. Ragab et al.
LUMINESCENCE (2017)
Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study
Raja Haranadha Babu Chunduri et al.
BIOMEDICAL CHROMATOGRAPHY (2016)
In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696)
S. Ayalasomayajula et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date
Jose Fernando Vilela-Martin
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Pharmacokinetic Drug-Drug Interaction Assessment of LCZ696 (an Angiotensin Receptor Neprilysin Inhibitor) With Omeprazole, Metformin or Levonorgestrel-Ethinyl Estradiol in Healthy Subjects
Lu Gan et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Derivative emission spectrofluorimetry: Application to the analysis of newly approved FDA combination of ibuprofen and famotidine in tablets
Marwa A. A. Ragab et al.
LUMINESCENCE (2015)
Pharmacokinetic Drug-Drug Interaction Assessment Between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Hydrochlorothiazide, Amlodipine, or Carvedilol
Hsiu-ling Hsiao et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)
Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
Orly Vardeny et al.
JACC-HEART FAILURE (2014)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Simultaneous determination of sulpiride and its alkaline degradation product by second derivative synchronous fluorescence spectroscopy
Amina Abdelal et al.
TALANTA (2009)
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Puja K. Mehta et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
Interaction of cromolyn sodium with human serum albumin: A fluorescence quenching study
YJ Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Share Paper
